Parasites and poor antenatal care are the main causes of epilepsy in sub-Saharan Africa, study reveals
31 January 2013
Epilepsy is one of the most common neurological conditions worldwide, and it is well known that it is significantly more prevalent in poorer countries and rural areas. The study of more than half a million people in five countries of sub-Saharan Africa is the first to reveal the true extent of the problem and the impact of different risk factors.
The study - conducted at International Network for the Demographic Evaluation of Populations and Their Health (INDEPTH) demographic surveillance sites in Kenya, South Africa, Uganda, Tanzania and Ghana - screened 586 607 residents and identified 1711 who were diagnosed as having active convulsive epilepsy.
These individuals, along with 2033 who did not have epilepsy, were given a questionnaire to complete about their lifestyle habits. The team also took blood samples to test for exposure to malaria, HIV and four other parasitic diseases that are common in low-income countries.
The team found that adults who had been exposed to parasitic diseases were 1.5 to 3 times more likely to have epilepsy than those who had not. Epilepsy has previously been linked with various parasite infections, but this is the first study to reveal the extent of the problem.
Professor Charles Newton from the Wellcome Trust programme at the Kenyan Medical Research Institute (KEMRI) and the Department of Psychiatry at Oxford University, who led the study, said: "This study demonstrates that many cases of epilepsy could be entirely preventable with elimination of parasites in Africa, some of which - for example, onchocerciasis - have been controlled in some areas. In some areas the incidence of epilepsy could be reduced by 30-60 per cent with appropriate control measures."
In children, the greatest risk factors for developing epilepsy were complications associated with delivery and head injury. Interventions to improve antenatal and perinatal care could substantially reduce the prevalence of epilepsy in this region, say the authors.
The study focused on people with convulsive epilepsies as they are the most reliably detected and reported and there remains a substantial stigma attached to patients with the disease.
“Facilities for diagnosis, treatment and ongoing management of epilepsy are virtually non-existent in many of the world's poorest regions, so it's vital that we take these simple steps to try and prevent as many cases of this debilitating disease as possible,” Professor Newton added.
The findings were published today in the journal 'Lancet Neurology'. The study was funded by the Wellcome Trust, with support from the University of the Witwatersrand and the South African Medical Research Council.
Image: An EEG recording. Credit: C Newton.
Senior Media Officer, Wellcome Trust
T +44 20 7611 7262
Communications Officer, KEMRI-Wellcome Trust Research Programme
T +254 (20) 2720163 /2715160
M +254 (0) 734 266044
Notes for editors
Ngugi AK et al. Prevalence of active convulsive epilepsy in sub-Saharan Africa and associated risk factors: cross-sectional and case-control studies. Lancet Neurol 2013.
About the KEMRI-Wellcome Trust Research Programme
The KEMRI-Wellcome Trust Research Programme is well known internationally for its work tackling malaria and other infectious diseases, particularly bacterial and viral childhood infections. With links to the Trust since the 1940s, the Programme was formally established in 1989, in partnership with the Kenya Medical Research Institute (KEMRI). It conducts basic and clinical research in parallel, with results feeding directly into local and international health policy, and aims to expand the country's capacity to conduct multidisciplinary research that is strong, sustainable and internationally competitive.
About the Wellcome Trust
The Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. It supports the brightest minds in biomedical research and the medical humanities. The Trust's breadth of support includes public engagement, education and the application of research to improve health. It is independent of both political and commercial interests.
About Oxford University's Medical Sciences Division
Oxford University's Medical Sciences Division is one of the largest biomedical research centres in Europe, with over 2,500 people involved in research and more than 2,800 students. The University is rated the best in the world for medicine, and it is home to the UK's top-ranked medical school.
From the genetic and molecular basis of disease to the latest advances in neuroscience, Oxford is at the forefront of medical research. It has one of the largest clinical trial portfolios in the UK and great expertise in taking discoveries from the lab into the clinic. Partnerships with the local NHS Trusts enable patients to benefit from close links between medical research and healthcare delivery.
A great strength of Oxford medicine is its long-standing network of clinical research units in Asia and Africa, enabling world-leading research on the most pressing global health challenges such as malaria, TB, HIV/AIDS and flu. Oxford is also renowned for its large-scale studies which examine the role of factors such as smoking, alcohol and diet on cancer, heart disease and other conditions.